vs
Side-by-side financial comparison of BALCHEM CORP (BCPC) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
BALCHEM CORP is the larger business by last-quarter revenue ($270.7M vs $168.4M, roughly 1.6× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 8.1%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 7.5%).
Balchem Corp is a global specialty chemicals and nutritional ingredients provider that develops, manufactures and distributes application-specific products for human nutrition, animal health, pharmaceutical and industrial end markets, serving customers across North America, Europe and Asia Pacific.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
BCPC vs ESPR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $270.7M | $168.4M |
| Net Profit | $40.3M | — |
| Gross Margin | — | — |
| Operating Margin | 20.5% | 50.6% |
| Net Margin | 14.9% | — |
| Revenue YoY | 8.1% | 143.7% |
| Net Profit YoY | 8.7% | — |
| EPS (diluted) | $1.25 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $270.7M | — | ||
| Q4 25 | $263.6M | $168.4M | ||
| Q3 25 | $267.6M | $87.3M | ||
| Q2 25 | $255.5M | $82.4M | ||
| Q1 25 | $250.5M | $65.0M | ||
| Q4 24 | $240.0M | $69.1M | ||
| Q3 24 | $239.9M | $51.6M | ||
| Q2 24 | $234.1M | $73.8M |
| Q1 26 | $40.3M | — | ||
| Q4 25 | $39.2M | — | ||
| Q3 25 | $40.3M | $-31.3M | ||
| Q2 25 | $38.3M | $-12.7M | ||
| Q1 25 | $37.1M | $-40.5M | ||
| Q4 24 | $33.6M | — | ||
| Q3 24 | $33.8M | $-29.5M | ||
| Q2 24 | $32.1M | $-61.9M |
| Q1 26 | — | — | ||
| Q4 25 | 35.6% | — | ||
| Q3 25 | 35.7% | — | ||
| Q2 25 | 36.4% | — | ||
| Q1 25 | 35.2% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 35.6% | — | ||
| Q2 24 | 35.5% | — |
| Q1 26 | 20.5% | — | ||
| Q4 25 | 19.8% | 50.6% | ||
| Q3 25 | 20.4% | -11.4% | ||
| Q2 25 | 20.1% | 8.6% | ||
| Q1 25 | 20.4% | -34.0% | ||
| Q4 24 | 19.8% | -6.4% | ||
| Q3 24 | 20.0% | -31.0% | ||
| Q2 24 | 19.6% | 3.5% |
| Q1 26 | 14.9% | — | ||
| Q4 25 | 14.9% | — | ||
| Q3 25 | 15.1% | -35.9% | ||
| Q2 25 | 15.0% | -15.4% | ||
| Q1 25 | 14.8% | -62.2% | ||
| Q4 24 | 14.0% | — | ||
| Q3 24 | 14.1% | -57.2% | ||
| Q2 24 | 13.7% | -83.9% |
| Q1 26 | $1.25 | — | ||
| Q4 25 | $1.21 | $0.32 | ||
| Q3 25 | $1.24 | $-0.16 | ||
| Q2 25 | $1.17 | $-0.06 | ||
| Q1 25 | $1.13 | $-0.21 | ||
| Q4 24 | $1.03 | $-0.14 | ||
| Q3 24 | $1.03 | $-0.15 | ||
| Q2 24 | $0.98 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $72.9M | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $-302.0M |
| Total Assets | $1.7B | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $72.9M | — | ||
| Q4 25 | $74.6M | $167.9M | ||
| Q3 25 | $65.1M | $92.4M | ||
| Q2 25 | $65.4M | $86.1M | ||
| Q1 25 | $49.9M | $114.6M | ||
| Q4 24 | $49.5M | $144.8M | ||
| Q3 24 | $73.7M | $144.7M | ||
| Q2 24 | $63.7M | $189.3M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $-302.0M | ||
| Q3 25 | $1.3B | $-451.4M | ||
| Q2 25 | $1.3B | $-433.5M | ||
| Q1 25 | $1.2B | $-426.2M | ||
| Q4 24 | $1.1B | $-388.7M | ||
| Q3 24 | $1.2B | $-370.2M | ||
| Q2 24 | $1.1B | $-344.2M |
| Q1 26 | $1.7B | — | ||
| Q4 25 | $1.7B | $465.9M | ||
| Q3 25 | $1.7B | $364.0M | ||
| Q2 25 | $1.7B | $347.1M | ||
| Q1 25 | $1.6B | $324.0M | ||
| Q4 24 | $1.6B | $343.8M | ||
| Q3 24 | $1.6B | $314.1M | ||
| Q2 24 | $1.6B | $352.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $40.1M | $45.2M |
| Free Cash FlowOCF − Capex | $33.8M | — |
| FCF MarginFCF / Revenue | 12.5% | — |
| Capex IntensityCapex / Revenue | 2.3% | 0.0% |
| Cash ConversionOCF / Net Profit | 0.99× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $40.1M | — | ||
| Q4 25 | $67.3M | $45.2M | ||
| Q3 25 | $65.6M | $-4.3M | ||
| Q2 25 | $47.3M | $-31.4M | ||
| Q1 25 | $36.5M | $-22.6M | ||
| Q4 24 | $52.3M | $-35.0M | ||
| Q3 24 | $51.3M | $-35.3M | ||
| Q2 24 | $45.0M | $-7.2M |
| Q1 26 | $33.8M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-35.5M | ||
| Q2 24 | — | $-7.3M |
| Q1 26 | 12.5% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -68.7% | ||
| Q2 24 | — | -9.9% |
| Q1 26 | 2.3% | — | ||
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.1% |
| Q1 26 | 0.99× | — | ||
| Q4 25 | 1.72× | — | ||
| Q3 25 | 1.63× | — | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 0.98× | — | ||
| Q4 24 | 1.56× | — | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 1.40× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCPC
Segment breakdown not available.
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
